MX354752B - Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. - Google Patents

Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.

Info

Publication number
MX354752B
MX354752B MX2013003238A MX2013003238A MX354752B MX 354752 B MX354752 B MX 354752B MX 2013003238 A MX2013003238 A MX 2013003238A MX 2013003238 A MX2013003238 A MX 2013003238A MX 354752 B MX354752 B MX 354752B
Authority
MX
Mexico
Prior art keywords
recombinant adenovirus
malaria
boosting composition
subject
adenovirus vector
Prior art date
Application number
MX2013003238A
Other languages
English (en)
Other versions
MX2013003238A (es
Inventor
Radosevic Katarina
Rodriguez Munoz Ariane
Alida Corina Lemckert Angelique
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2013003238A publication Critical patent/MX2013003238A/es
Publication of MX354752B publication Critical patent/MX354752B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a el uso de (i) una composición de sensibilización que comprende un antígeno proteináceo con adyuvante que comprende proteína de circumsporozoito (CS) o una parte inmunogénica de la misma de un parásito causante de malaria; (ii) una primera composición de refuerzo que comprende un vector de adenovirus recombinante de Ad35 que comprende ácido nucleico que codifica proteína de CS o una parte inmunogénica de la misma de un parásito causante de malaria; y (iii) una segunda composición de refuerzo que comprende un vector de adenovirus recombinante de Ad26 que comprende ácido nucleico que codifica proteína de CS o una parte inmunogénica de la misma de un parásito causante de malaria, para la manufactura de un medicamento para inducir una respuesta inmunológica en un sujeto contra un antígeno de un parásito causante de malaria, en donde dichas composiciones están adaptadas para ser administrables por separado a un sujeto, primero la composición de sensibilización, posteriormente la primera composición de refuerzo, y finalmente la segunda composición de refuerzo.
MX2013003238A 2010-09-27 2011-09-07 Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. MX354752B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40415610P 2010-09-27 2010-09-27
EP10180251 2010-09-27
PCT/EP2011/065434 WO2012041669A1 (en) 2010-09-27 2011-09-07 Heterologous prime boost vaccination regimen against malaria

Publications (2)

Publication Number Publication Date
MX2013003238A MX2013003238A (es) 2013-05-30
MX354752B true MX354752B (es) 2018-03-20

Family

ID=43416881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003238A MX354752B (es) 2010-09-27 2011-09-07 Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.

Country Status (6)

Country Link
US (1) US9168292B2 (es)
AU (1) AU2011310838B2 (es)
BR (1) BR112013004582A2 (es)
CA (1) CA2809463C (es)
MX (1) MX354752B (es)
WO (1) WO2012041669A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
SG11201610446XA (en) 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US11065320B2 (en) 2016-04-12 2021-07-20 Oxford University Innovation Limited Prime target
CA3133971A1 (en) * 2019-03-20 2020-09-24 Turnstone Biologics Inc. Sequential heterologous boost oncolytic viral mmunotherapy
US20220305099A1 (en) * 2019-08-27 2022-09-29 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
EP0614465B1 (en) 1991-11-16 1999-03-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
PT833934E (pt) 1995-06-15 2005-02-28 Crucell Holland Bv Sistemas de empacotamento para adenovivrus recombinente humano destinados a terapia genetica
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6005009A (en) 1997-03-19 1999-12-21 Duke University Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
BR9908015A (pt) 1998-02-17 2001-04-24 Schering Corp Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2000029024A1 (en) 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
DK1818408T3 (da) 1999-05-17 2011-10-17 Crucell Holland Bv Rekombinant adenovirus af serotypen Ad11
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
RU2004125283A (ru) 2002-01-18 2005-06-10 Шеринг Акциенгезельшафт (De) Стабилизированные композиции аденовируса
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
EP1569515A4 (en) * 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa MALARIA vaccine method
US20050208078A1 (en) * 2003-11-20 2005-09-22 Hoffman Stephen L Methods for the prevention of malaria
CA2507915C (en) * 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
SI1802336T1 (sl) * 2004-10-14 2012-01-31 Crucell Holland Bv Začetna/obnovitvena cepiva proti malariji
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
KR101504392B1 (ko) 2008-11-03 2015-03-19 크루셀 홀란드 비.브이. 아데노바이러스 벡터의 제조방법
NZ601424A (en) 2010-02-15 2014-07-25 Crucell Holland Bv Method for the production of ad26 adenoviral vectors

Also Published As

Publication number Publication date
US9168292B2 (en) 2015-10-27
AU2011310838A1 (en) 2013-03-28
CA2809463C (en) 2021-05-25
CA2809463A1 (en) 2012-04-05
BR112013004582A2 (pt) 2016-09-06
AU2011310838B2 (en) 2015-11-05
US20130216580A1 (en) 2013-08-22
WO2012041669A1 (en) 2012-04-05
MX2013003238A (es) 2013-05-30

Similar Documents

Publication Publication Date Title
MX354752B (es) Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
IL214460A0 (en) Malaria prime/boost vaccines
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
WO2020128031A3 (en) Rna for malaria vaccines
WO2007027860A3 (en) Adenoviral vector-based malaria vaccines
EA200901060A1 (ru) Новый способ и композиции
MX2009010870A (es) Vector adenoviral que codifica el antigeno de malaria.
MX360415B (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
SG156535A1 (en) Recombinant viral-based malaria vaccines
MX363529B (es) Vesículas de membrana externa.
NZ757882A (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
WO2009025770A3 (en) A heterologous prime-boost immunization regimen
MX363671B (es) Proteína central y proteína del antígeno de superficie del virus de la hepatitis b y vacunas comprenden éstas.
MX2009000655A (es) Vacunasd para malaria.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
EA201290675A1 (ru) Вакцинные векторы и способы усиления иммунных ответов
MX2014011713A (es) Composiciones y procedimientos antipaludismo.
WO2008086386A8 (en) Adenoviral vector-based malaria vaccines
EA201171347A1 (ru) Комбинированная вакцина против кори и малярии
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2008127307A3 (en) Induction of an immune response against dengue virus using prime-boost approach
PL391384A1 (pl) Kompleks rybosomalnych białek P z zarodźca malarii Plasmodium falciparum jako antygen patogenu malarii oraz sposób otrzymania tego antygenu i kaseta ekspresyjna, zwłaszcza do tego sposobu
WO2010127420A9 (pt) Sequências geneticamente modificadas de antígenos de plasmodium vivax
WO2011133870A3 (en) Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)

Legal Events

Date Code Title Description
FG Grant or registration